32.9 C
August 16, 2022

Biofarm targets a 16% increase in turnover in 2022

Biofarm, one of the most important drug producers in Romania, estimates a 16% increase in turnover for this year, after recording a value of 239 million lei and an EBITDA of approximately 2021 in 2021 82 million lei, and for 2022 it aims to increase it by 15% compared to the end of the year.

We ended the year 2021 with very good results and we are confident that the investments budgeted for this year will contribute to the increase of sales. Cutting-edge equipment enables us to increase production and expand into new markets. We have strong premises for meeting the objectives, despite the challenges created by the increase in production costs caused by the estimated cost variations for the supply of raw materials, utilities. Even in this context, I am confident that, at the end of the year, we will strengthen our market share and continue to be one of the leading players in the local pharmaceutical industry in the Consumer Healthcare (CHC) category”, said Cătălin Vicol, General Manager of Biofarm.

According to the financial results, in 2021, Biofarm’s situation was very good, economically stable, resulting in an EBITDA margin of 34%. Given the fact that the pharmaceutical market is on an upward trend, the company targets a 10% higher profit this year compared to the previous year. These estimates are based on a well-defined strategy that is supported by three objectives: increasing sales of products in the portfolio, launching new products and expanding into new markets.

By understanding the lifestyle and social contexts of employees, the company is committed to meeting their needs. Thus, the increase in salary expenses for 2022 is one of the company’s efforts to show concern for them.

Innovation is part of Biofarm’s DNA, with each team member working day in and day out for people and their health. Biofarm regularly certifies and recertifies to the highest international standard all systems, production lines and any other aspect related to the company’s promise to deliver safe and best quality products.

Currently, Biofarm is the largest Romanian manufacturer of soft gelatin capsules, among the top three Romanian manufacturers of solutions and suspensions for oral administration and one of the largest manufacturers of tablets and drops in Romania. Biofarm products are currently reaching 12 countries around the world, and in the future, according to Biofarm’s long-term business development plans, they will be on the shelves of pharmacies in several countries in Southeast Europe, Central Asia. and Southeast, Africa and the Arabian area.

Related posts

Anna Heijker, owner of Pitches & Presentations: ‘Traditional event programs comprising of three keynote speakers and a panel discussion don’t work anymore’

Nine O' Clock

Infringement because of gas export ban, confirmed

Nine O' Clock

World Bank: Romania to benefit from loan worth 500 million euro to back sustainable economic growth

Nine O' Clock